The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Nanomedicines: addressing the scientific and regulatory gap
Abstract
Nanomedicine is the application of nanotechnology to the discipline of medicine: the use of nanoscale materials for the diagnosis, monitoring, control, prevention, and treatment of disease. Nanomedicine holds tremendous promise to revolutionize medicine across disciplines and specialties, but this promise has yet to be fully realized. Beyond the typical complications associated with drug development, the fundamentally different and novel physical and chemical properties of some nanomaterials compared to materials on a larger scale (i.e., their bulk counterparts) can create a unique set of opportunities as well as safety concerns, which have only begun to be explored. As the research community continues to investigate nanomedicines, their efficacy, and the associated safety issues, it is critical to work to close the scientific and regulatory gaps to assure that nanomedicine drives the next generation of biomedical innovation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Self-citationPharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Self-citationGabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Self-citationTransport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,378
Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery
Paciotti, G. F., Myer, L., Weinreich, D., Goia, D., Pavel, N., McLaughlin, R. E., & Tamarkin, L. (2004) · Drug Delivery · doi:10.1080/10717540490433895 · Cited by 1,185
Self-citationPolymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
Maeda, H., Bharate, G. Y., & Daruwalla, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.11.010 · Cited by 1,168
Haran, G., Cohen, R., Bar, L. K., & Barenholz, Y. (1993) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(93)90105-9 · Cited by 934
Self-citationProtein nanoparticles as drug carriers in clinical medicine
Hawkins, M. J., Soon-Shiong, P., & Desai, N. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.044 · Cited by 779
Self-citationPhase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
Libutti, S. K., Paciotti, G. F., Byrnes, A. A., Alexander, H. R., Gannon, W. E., Walker, M., Seidel, G. D., Yuldasheva, N., & Tamarkin, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0978 · Cited by 710
Self-citationLiposome application: problems and prospects.
Barenholz, Y. (2001) · Current Opinion in Colloid & Interface Science · doi:10.1016/s1359-0294(00)00090-x · Cited by 659
Self-citation
Cited by
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 6,684
Advances and Challenges of Liposome Assisted Drug Delivery
Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00286 · Cited by 2,632
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Diverse Applications of Nanomedicine
Pelaz, B., Alexiou, C., Alvarez-Puebla, R. A., Alves, F., Andrews, A. M., Ashraf, S., Balogh, L. P., Ballerini, L., Bestetti, A., Brendel, C., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06040 · Cited by 1,350
Targeted drug delivery strategies for precision medicines
Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,183
Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00437 · Cited by 1,101
Nanoparticle colloidal stability in cell culture media and impact on cellular interactions
Moore, T. L., Rodriguez-Lorenzo, L., Hirsch, V., Balog, S., Urban, D., Jud, C., Rothen-Rutishauser, B., Lattuada, M., & Petri-Fink, A. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00487f · Cited by 1,082
Hua, S., de Matos, M. B. C., Metselaar, J. M., & Storm, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00790 · Cited by 1,048
Cancer nanomedicine: A review of recent success in drug delivery
Tran, S., DeGiovanni, P., Piel, B., & Rai, P. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0175-0 · Cited by 879
Innovative approaches for cancer treatment: current perspectives and new challenges
Pucci, C., Martinelli, C., & Ciofani, G. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.961 · Cited by 814
Nanomedicine: Principles, Properties, and Regulatory Issues
Soares, S., Sousa, J., Pais, A., & Vitorino, C. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00360 · Cited by 790
Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities
Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., & Hamblin, M. R. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0120 · Cited by 664
Nanotechnologies in Food Science: Applications, Recent Trends, and Future Perspectives
Nile, S. H., Baskar, V., Selvaraj, D., Nile, A., Xiao, J., & Kai, G. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-0383-9 · Cited by 631
Nanoparticles in Daily Life: Applications, Toxicity and Regulations
Gupta, R., & Xie, H. (2018) · Journal of Environmental Pathology, Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.2018026009 · Cited by 553
Talelli, M., Barz, M., Rijcken, C. J. F., Kiessling, F., Hennink, W. E., & Lammers, T. (2015) · Nano Today · doi:10.1016/j.nantod.2015.01.005 · Cited by 506
Nanoparticles: Taking a Unique Position in Medicine
Joseph, T., Kar Mahapatra, D., Esmaeili, A., Piszczyk, Ł., Hasanin, M., Kattali, M., Haponiuk, J., & Thomas, S. (2023) · Nanomaterials · doi:10.3390/nano13030574 · Cited by 480
Regulatory aspects on nanomedicines
Sainz, V., Conniot, J., Matos, A. I., Peres, C., Zupanǒiǒ, E., Moura, L., Silva, L. C., Florindo, H. F., & Gaspar, R. S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.023 · Cited by 417
Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles
Alavi, M., & Hamidi, M. (2019) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2018-0032 · Cited by 405
Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures
Ragelle, H., Danhier, F., Préat, V., Langer, R., & Anderson, D. G. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1244187 · Cited by 390
Advances in Nanotechnology for Enhancing the Solubility and Bioavailability of Poorly Soluble Drugs
Liu, Y., Liang, Y., Yuhong, J., Xin, P., Han, J. L., Du, Y., Yu, X., Zhu, R., Zhang, M., Chen, W., et al. (2024) · Drug Design, Development and Therapy · doi:10.2147/dddt.s447496 · Cited by 365
BCS class IV drugs: Highly notorious candidates for formulation development
Ghadi, R., & Dand, N. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.014 · Cited by 361
Eleraky, N. E., Allam, A., Hassan, S. B., & Omar, M. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020142 · Cited by 342
A translational framework to DELIVER nanomedicines to the clinic
Joyce, P., Allen, C. J., Alonso, M. J., Ashford, M., Bradbury, M. S., Germain, M., Kavallaris, M., Langer, R., Lammers, T., Peracchia, M. T., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01754-7 · Cited by 333
Development of Pharmaceutical Nanomedicines: From the Bench to the Market
Halwani, A. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010106 · Cited by 324
Nanoscale Drug Delivery Systems: From Medicine to Agriculture
Vega-Vásquez, P., Mosier, N. S., & Irudayaraj, J. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00079 · Cited by 323
Progress, challenges, and future of nanomedicine
Zhang, C., Yan, L., Wang, X., Zhu, S., Chen, C., Gu, Z., & Zhao, Y. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101008 · Cited by 318
Okeke, E. S., Chukwudozie, K. I., Nyaruaba, R., Ita, R. E., Oladipo, A., Ejeromedoghene, O., Atakpa, E. O., Agu, C. V., & Okoye, C. O. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-22319-y · Cited by 316
PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up
Operti, M. C., Bernhardt, A., Grimm, S., Engel, A., Figdor, C. G., & Tagit, O. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120807 · Cited by 302
Nanomedicine applied to translational oncology: A future perspective on cancer treatment
Bregoli, L., Movia, D., Gavigan-Imedio, J. D., Lysaght, J., Reynolds, J., & Prina-Mello, A. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.08.006 · Cited by 296
Desai, N., Rana, D., Patel, M., Bajwa, N., Prasad, R., & Vora, L. K. (2025) · Small · doi:10.1002/smll.202502315 · Cited by 295
Self-citationJain, S., Patel, N., Shah, M. K., Khatri, P., & Vora, N. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.10.001 · Cited by 283
Biosafety of mesoporous silica nanoparticles; towards clinical translation
Lérida-Viso, A., Estepa-Fernández, A., García-Fernández, A., Martí-Centelles, V., & Martínez-Máñez, R. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115049 · Cited by 279
Padrela, L., Rodrigues, M. A., Duarte, A., Dias, A. M. A., Braga, M. E. M., & de Sousa, H. C. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.010 · Cited by 262
Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach?
Mühlebach, S. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.024 · Cited by 203
Self-citationChallenges of clinical translation in nanomedicine: A qualitative study
Satalkar, P., Elger, B. S., Hunziker, P., & Shaw, D. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.12.376 · Cited by 124
Artificial Intelligence Advancements in Oncology: A Review of Current Trends and Future Directions
Huhulea, E. N., Huang, L., Eng, S., Sumawi, B., Huang, A., Aifuwa, E., Hirani, R., Tiwari, R. K., & Etienne, M. (2025) · Biomedicines · doi:10.3390/biomedicines13040951 · Cited by 74
Drug-Loaded Biomimetic Carriers for Non-Hodgkin’s Lymphoma Therapy: Advances and Perspective
Li, X., Zhang, Y., Wang, C., Wang, L., Ye, Y., Xue, R., Shi, Y., Su, Q., Zhu, Y., & Wang, L. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c01480 · Cited by 4
Metadata
- Authors
- Tinkle, S., McNeil, S. E., Mühlebach, S., Bawa, R., Borchard, G., Barenholz, Y. (., Tamarkin, L., & Desai, N.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2014-03-27
- Volume
- 1313
- Issue
- 1
- Pages
- 35-56
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W1567847444
- Cited by
- 546
- References
- 30
- FWCI
- 12.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.